title: [Traceability of a resorbable implant for lipoatrophy: why should it be traced and how should this be done? Example of polylactic acid (Newfill)].
abstract: Facial lipoatrophy is a frequent adverse effect of HIV-infected patients due to antiretroviral therapy. Intradermal injection of polylactic acid (Newfill) is one of the currently available treatments. Newfill is a resorbable implant and follow-up has to be rigorous. The Pharmacy and the Infectious Diseases units at the Saint-Louis hospital implemented a follow-up procedure. A follow-up of treated patients was made for 20 months. 127 patients were included. The rate of traceability was 100%. Such traceability is therefore feasible and will have to be implemented for the follow-up of patients treated with future filling products.
authors.affiliation: Service de pharmacie, hôpital Saint-Louis, APHP, 1, avenue Claude-Vellefaux, 75475 Paris cedex 10, France. clodupont@hotmail.com
authors.forename: C
authors.initials: C
authors.lastname: Dupont
authors.forename: M
authors.initials: M
authors.lastname: Lafaurie
authors.forename: I
authors.initials: I
authors.lastname: Madelaine-Chambrin
authors.forename: M
authors.initials: M
authors.lastname: Macaux
authors.forename: J-M
authors.initials: JM
authors.lastname: Molina
authors.forename: P
authors.initials: P
authors.lastname: Faure
mesh_terms: D020341:Absorbable Implants; D005145:Face; D005260:Female; D039682:HIV-Associated Lipodystrophy Syndrome / Q000601:surgery*; D006801:Humans; D019344:Lactic Acid / Q000032:analysis*; D008297:Male; D011091:Polyesters; D011108:Polymers / Q000032:analysis*
chemical_list: D011091:Polyesters; D011108:Polymers; D019344:Lactic Acid; C033616:poly(lactide)